IL2 and neoplasm: The findings indicated no tumor shrinkage, as five individuals in the first cohort showed attention-requiring toxicities (grade 3/4; attributable to high-dose IL-2) whereas those in the second cohort exhibited milder signs of toxicities (grade 1/2) (97).